vs
Piedmont Realty Trust, Inc.（PDM）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Piedmont Realty Trust, Inc.的季度营收约是再鼎医药的1.1倍（$143.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 0.4%），过去两年再鼎医药的营收复合增速更高（20.8% vs 0.0%）
Piedmont Realty Trust是一家公开上市的房地产投资信托（REIT），主要持有、运营和投资美国高增长大都会区的优质写字楼资产，服务科技、专业服务、医疗等多个行业的企业租户，通过战略资产管理和投资组合优化为利益相关方提供稳定长期回报。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
PDM vs ZLAB — 直观对比
营收规模更大
PDM
是对方的1.1倍
$127.1M
营收增速更快
ZLAB
高出16.7%
0.4%
两年增速更快
ZLAB
近两年复合增速
0.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $143.3M | $127.1M |
| 净利润 | $-45.0M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | -31.4% | — |
| 营收同比 | 0.4% | 17.1% |
| 净利润同比 | -27.9% | — |
| 每股收益（稀释后） | $-0.10 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PDMZLAB
| Q1 26 | $143.3M | — | ||
| Q4 25 | $142.9M | $127.1M | ||
| Q3 25 | $139.2M | $115.4M | ||
| Q2 25 | $140.3M | $109.1M | ||
| Q1 25 | $142.7M | $105.7M | ||
| Q4 24 | $143.2M | $108.5M | ||
| Q3 24 | $139.3M | $101.8M | ||
| Q2 24 | $143.3M | $100.1M |
净利润PDMZLAB
| Q1 26 | $-45.0M | — | ||
| Q4 25 | $-43.2M | — | ||
| Q3 25 | $-13.5M | $-36.0M | ||
| Q2 25 | $-16.8M | $-40.7M | ||
| Q1 25 | $-10.1M | $-48.4M | ||
| Q4 24 | $-30.0M | — | ||
| Q3 24 | $-11.5M | $-41.7M | ||
| Q2 24 | $-9.8M | $-80.3M |
毛利率PDMZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% |
营业利润率PDMZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | -54.6% | ||
| Q3 25 | — | -42.3% | ||
| Q2 25 | — | -50.3% | ||
| Q1 25 | — | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | — | -66.6% | ||
| Q2 24 | — | -76.0% |
净利率PDMZLAB
| Q1 26 | -31.4% | — | ||
| Q4 25 | -30.3% | — | ||
| Q3 25 | -9.7% | -31.2% | ||
| Q2 25 | -12.0% | -37.3% | ||
| Q1 25 | -7.1% | -45.8% | ||
| Q4 24 | -20.9% | — | ||
| Q3 24 | -8.3% | -40.9% | ||
| Q2 24 | -6.8% | -80.2% |
每股收益（稀释后）PDMZLAB
| Q1 26 | $-0.10 | — | ||
| Q4 25 | $-0.34 | $-0.05 | ||
| Q3 25 | $-0.11 | $-0.03 | ||
| Q2 25 | $-0.14 | $-0.04 | ||
| Q1 25 | $-0.08 | $-0.04 | ||
| Q4 24 | $-0.25 | $-0.09 | ||
| Q3 24 | $-0.09 | $-0.04 | ||
| Q2 24 | $-0.08 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.3M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.5B | $715.5M |
| 总资产 | $4.0B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PDMZLAB
| Q1 26 | $2.3M | — | ||
| Q4 25 | $731.0K | $689.6M | ||
| Q3 25 | $3.0M | $717.2M | ||
| Q2 25 | $3.3M | $732.2M | ||
| Q1 25 | $2.9M | $757.3M | ||
| Q4 24 | $109.6M | $779.7M | ||
| Q3 24 | $133.6M | $616.1M | ||
| Q2 24 | $138.5M | $630.0M |
总债务PDMZLAB
| Q1 26 | — | — | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
股东权益PDMZLAB
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $715.5M | ||
| Q3 25 | $1.5B | $759.9M | ||
| Q2 25 | $1.5B | $791.7M | ||
| Q1 25 | $1.6B | $810.8M | ||
| Q4 24 | $1.6B | $840.9M | ||
| Q3 24 | $1.6B | $667.7M | ||
| Q2 24 | $1.7B | $704.2M |
总资产PDMZLAB
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | $1.2B | ||
| Q3 25 | $4.0B | $1.2B | ||
| Q2 25 | $4.0B | $1.2B | ||
| Q1 25 | $4.0B | $1.2B | ||
| Q4 24 | $4.1B | $1.2B | ||
| Q3 24 | $4.1B | $985.3M | ||
| Q2 24 | $4.2B | $987.4M |
负债/权益比PDMZLAB
| Q1 26 | — | — | ||
| Q4 25 | 1.49× | — | ||
| Q3 25 | 1.43× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.40× | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | 1.36× | — | ||
| Q2 24 | 1.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | 110.3% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流PDMZLAB
| Q1 26 | — | — | ||
| Q4 25 | $140.6M | $-26.0M | ||
| Q3 25 | $35.8M | $-32.0M | ||
| Q2 25 | $50.1M | $-31.0M | ||
| Q1 25 | $3.7M | $-61.7M | ||
| Q4 24 | $198.1M | $-55.8M | ||
| Q3 24 | $42.9M | $-26.8M | ||
| Q2 24 | $66.8M | $-42.2M |
自由现金流PDMZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | — | $-58.4M | ||
| Q3 24 | — | $-28.2M | ||
| Q2 24 | — | $-42.9M |
自由现金流率PDMZLAB
| Q1 26 | — | — | ||
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | — | -53.8% | ||
| Q3 24 | — | -27.7% | ||
| Q2 24 | — | -42.9% |
资本支出强度PDMZLAB
| Q1 26 | 110.3% | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 0.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PDM
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
